Stock analysts at Oppenheimer Holdings, Inc. initiated coverage on shares of Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) in a report released on Thursday. The firm set a “market perform” rating on the stock.

A number of other research firms also recently weighed in on PCRX. Wedbush restated an “outperform” rating and set a $87.00 price target on shares of Pacira Pharmaceuticals in a report on Wednesday, August 23rd. Mizuho restated a “buy” rating and set a $54.00 price target on shares of Pacira Pharmaceuticals in a report on Wednesday, July 26th. Royal Bank Of Canada set a $58.00 price target on shares of Pacira Pharmaceuticals and gave the company a “buy” rating in a report on Monday, May 15th. ValuEngine downgraded shares of Pacira Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, August 4th. Finally, BidaskClub downgraded shares of Pacira Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Wednesday, August 2nd. Two analysts have rated the stock with a sell rating, nine have given a hold rating and nine have given a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $53.00.

Pacira Pharmaceuticals (PCRX) opened at 37.15 on Thursday. Pacira Pharmaceuticals has a one year low of $29.95 and a one year high of $58.95. The firm has a 50-day moving average price of $38.74 and a 200 day moving average price of $44.82. The firm’s market capitalization is $1.50 billion.

Pacira Pharmaceuticals (NASDAQ:PCRX) last released its quarterly earnings results on Wednesday, August 2nd. The company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by $0.06. The business had revenue of $70.90 million for the quarter, compared to the consensus estimate of $73.37 million. Pacira Pharmaceuticals had a negative net margin of 23.36% and a negative return on equity of 12.44%. The firm’s revenue for the quarter was up 1.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.21 EPS. Equities research analysts anticipate that Pacira Pharmaceuticals will post ($0.17) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This report was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this report on another domain, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/09/07/pacira-pharmaceuticals-inc-pcrx-earns-market-perform-rating-from-analysts-at-oppenheimer-holdings-inc.html.

In other news, Director Paul J. Hastings sold 1,044 shares of the business’s stock in a transaction dated Tuesday, August 22nd. The shares were sold at an average price of $36.15, for a total transaction of $37,740.60. Following the transaction, the director now owns 3,518 shares in the company, valued at approximately $127,175.70. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO David M. Stack sold 28,885 shares of the business’s stock in a transaction dated Tuesday, August 15th. The stock was sold at an average price of $36.37, for a total transaction of $1,050,547.45. Following the transaction, the chief executive officer now owns 159,164 shares in the company, valued at approximately $5,788,794.68. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 33,390 shares of company stock worth $1,215,480. Insiders own 6.60% of the company’s stock.

Several large investors have recently bought and sold shares of the company. Principal Financial Group Inc. increased its holdings in shares of Pacira Pharmaceuticals by 5.2% during the 2nd quarter. Principal Financial Group Inc. now owns 5,466 shares of the company’s stock worth $261,000 after purchasing an additional 270 shares during the period. Ameritas Investment Partners Inc. increased its holdings in shares of Pacira Pharmaceuticals by 9.6% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,449 shares of the company’s stock worth $165,000 after purchasing an additional 302 shares during the period. Benjamin F. Edwards & Company Inc. increased its holdings in shares of Pacira Pharmaceuticals by 12.2% during the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 2,794 shares of the company’s stock worth $133,000 after purchasing an additional 303 shares during the period. Denver Investment Advisors LLC increased its holdings in shares of Pacira Pharmaceuticals by 6.8% during the 2nd quarter. Denver Investment Advisors LLC now owns 6,850 shares of the company’s stock worth $327,000 after purchasing an additional 435 shares during the period. Finally, Amalgamated Bank increased its holdings in shares of Pacira Pharmaceuticals by 12.7% during the 2nd quarter. Amalgamated Bank now owns 5,030 shares of the company’s stock worth $240,000 after purchasing an additional 566 shares during the period.

About Pacira Pharmaceuticals

Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.

Analyst Recommendations for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Ratings for Pacira Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.